Menu
+
+
+
+
+
+
Interim data from the single-blind, U.S. Phase IIa EB-1020-ADHD-201 trial in 40 adult male ADHD patients showed that 150-250 mg doses of twice-daily EB-1020 SR significantly improved ADHD-RS-IV score by 22.4 points at week 4...
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.
